Open AccessEstablishment of the enzyme‐linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin
Author(s) -
Nakaishi Masayuki,
Kajino Kazunori,
Ikesue Masahiro,
Hagiwara Yoshiaki,
Kuwahara Maki,
Mitani Hiroaki,
HorikoshiSakuraba Yuko,
Segawa Tatsuya,
Kon Shigeyuki,
Maeda Masahiro,
Wang Tegexibaiyin,
Abe Masaaki,
Yokoyama Masayoshi,
Hino Okio
Publication year - 2007
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2007.00438.x
Subject(s) - mesothelin , mesothelioma , antibody , kidney , cancer , immunohistochemistry , enzyme , pathology , biology , carcinoma , medicine , cancer research , microbiology and biotechnology , endocrinology , immunology , biochemistry
By representational difference analysis, we previously identified the rat Erc (Expressed in renal carcinoma) gene that was more abundantly expressed in the renal carcinoma tissues of Eker rats than in the rat normal kidney. In this study, we raised antibodies against the amino‐terminal portion of the rat Erc, and demonstrated the existence of a ∼30‐kDa secretory form in the supernatant of cultured cells derived from rat renal carcinoma. The enzyme‐linked immunosorbent assay (ELISA) system using these antibodies detected high concentrations of this form in the sera of Eker rats bearing renal carcinomas, and in the sera of rats transplanted with mesothelioma cells. Mesothelin, a human homolog of the rat Erc, was recently reported to be a serum marker of malignant mesothelioma. The prognosis of mesothelioma is poor and there is no effective treatment at present. There are several rat model systems of mesothelioma that may be promising tools in the development of an antimesothelioma treatment. We hope our ELISA to detect the soluble form of rat Erc/Mesothelin is useful in the rat model system to exploit the antimesothelioma therapy to be used in human cases. ( Cancer Sci 2007; 98: 659–664)